UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C.  20549

                               FORM 10-Q/A






                       AMENDMENT NO. 3 TO
        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                  THE SECURITIES EXCHANGE ACT OF 1934

              For quarterly period ended   March 31, 1999
                                           --------------




                      Commission file number 0-15975
                                             -------


                                LabOne, Inc.
                                ------------
                              10101 Renner Blvd
                             Lenexa, Kansas 66219


                               (913) 888-1770


                           Incorporated in Delaware
             I.R.S. Employer Identification Number:  48-0952323






    Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.     Yes /X/     No / /

Number of shares outstanding of the only class of Registrant's common stock,
$.01 par value, as of May 1, 1999 - 13,311,450 shares net of  1,688,550 shares
held as treasury stock.








                                  Page 1 of 13

<TABLE>                 PART I.  FINANCIAL INFORMATION
ITEM 1 - Financial Statements
                              LabOne, Inc. and Subsidiaries
                         Consolidated Balance Sheets (as restated)
<S>                                                             <C>            <C>
                                                                   March 31,     December 31,
                                                                      1999            1998
ASSETS                                                             ---------        ---------
Current assets:
   Cash and cash equivalents                                      $6,918,256       10,177,740
   Accounts receivable-trade, net of allowance for doubtful
     accounts of $2,863,670 in 1999 and $2,326,716 in 1998        19,696,648       18,735,984
   Income taxes receivable                                           177,799          282,229
   Inventories                                                     1,360,762        1,798,481
   Real estate available for sale                                  1,793,207        3,515,000
   Prepaid expenses and other current assets                       2,488,127        2,504,768
   Deferred income taxes                                           3,284,203        3,972,575
                                                                  ----------       ----------
      Total current assets                                        35,719,002       40,986,777
Property, plant and equipment                                     76,360,991       72,915,797
   Less accumulated depreciation                                  34,652,381       35,983,169
                                                                  ----------       ----------
      Net property, plant and equipment                           41,708,610       36,932,628
Other assets:
   Intangible assets, net of accumulated amortization              7,102,158        7,414,319
Bond issue costs, net of accumulated amortization
     of $10,190 in 1999 and $5,823 in 1998                           181,957          186,324
   Deposits and other assets                                         210,550          206,127
                                                                   ---------       ----------
      Total assets                                               $84,922,277       85,726,175
                                                                  ==========       ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Accounts payable                                              $ 5,310,712        4,353,733
   Retainage and construction payable                              3,473,065        3,809,193
   Current portion of long-term debt                               1,862,602        1,860,168
   Accrued payroll and benefits                                    3,083,031        4,148,593
   Other accrued expenses                                            566,871          610,315
   Other current liabilities                                         344,044          274,198
                                                                   ----------      ----------
      Total current liabilities                                   14,640,325       15,056,200
   Long-term debt                                                 18,094,181       18,097,308
   Deferred income taxes - noncurrent                                169,377           27,087
                                                                  ----------       ----------
      Total liabilities                                           32,903,883       33,180,595
Stockholders' equity:
   Preferred stock, $.01 par value per share;
     1,000,000 shares authorized, none issued                            -                -
   Common stock, $.01 par value per share; 40,000,000 shares
     authorized, 15,000,000 shares issued                            150,000          150,000
   Additional paid-in capital                                     14,099,066       14,099,066
   Equity adjustment from foreign currency translation              (833,623)        (849,098)
   Retained earnings                                              58,810,067       59,352,728
                                                                  ----------       ----------
                                                                  72,225,510       72,752,696
   Less treasury stock of 1,688,550 shares in
     1999 and 1998                                                20,207,116       20,207,116
                                                                  ----------       ----------
      Total stockholders' equity                                  52,018,394       52,545,580
                                                                  ----------       ----------
      Total liabilities and stockholders' equity                 $84,922,277      $85,726,175
                                                                  ==========       ==========
See accompanying notes to consolidated financial statements and management's discussion and
analysis of financial condition and results of operations.
                                   Page 2


</TABLE>
                        LabOne, Inc. and Subsidiaries
                     Consolidated Statements of Earnings
                               (as restated)

                                                 Three months ended March 31,
                                                       1999           1998
                                                    ----------     ----------

Sales                                             $ 27,328,085     23,333,434

Cost of sales                                       15,651,339     12,958,948
                                                    ----------     ----------
     Gross profit                                   11,676,746     10,374,486

Selling, general and administrative expenses         8,564,085      7,448,411
                                                    ----------     ----------
     Earnings from operations                        3,112,661      2,926,075

Interest expense                                      (289,673)          -
Interest income and other                               87,675        232,899
                                                    ----------     ----------
     Earnings before income taxes                    2,910,663      3,158,974

Income tax expense                                   1,057,263      1,241,782
                                                    ----------     ----------
     Net earnings                                  $ 1,853,400      1,917,192
                                                    ==========     ==========


Basic earnings per common share                        $ 0.14           0.15
                                                       ======         ======
Diluted earnings per common share                      $ 0.14           0.14
                                                       ======         ======

Dividends per common share                             $ 0.18           0.18
                                                       ======         ======

Basic weighted average common shares outstanding   13,311,450     13,134,883
                                                   ==========     ==========

Diluted weighted average common shares outstanding 13,339,471     13,318,945
                                                   ==========     ==========











See accompanying notes to consolidated financial statements and management's
discussion and analysis of financial condition and results of operations.


                                   Page 3

                         LabOne, Inc. and Subsidiaries
                Consolidated Statement of Stockholders' Equity (as restated)
                      Three Months Ended March 31, 1999

<TABLE>
<CAPTION>
                                              Accumulated
                                  Additional     other                                Total
                         Common     paid-in  comprehensive  Retained     Treasury   stockholders' Comprehensive
                         stock      capital      income     earnings       stock      equity         income
<S>                   <C>        <C>          <C>         <C>          <C>         <C>             <C>
Balance at
  December 31, 1998    $150,000   14,099,066   (849,098)   59,352,728   (20,207,116)  52,545,580
Comprehensive income:
  Net earnings                                              1,853,400                  1,853,400      1,853,400
  Equity adjustment
   from foreign
   currency translation                          15,475                                   15,475         15,475
                                                                                                      ---------
Comprehensive income                                                                                  1,868,875
                                                                                                      =========
Cash dividends
   ($0.18 per share)                                       (2,396,061)                (2,396,061)
                       --------   ----------  ---------   -----------   ----------   -----------
Balance at
   March 31, 1999      $150,000   14,099,066   (833,623)   58,810,067   (20,207,116)  52,018,394
                       ========   ==========   =========   ==========   ===========   ==========

</TABLE>




















See accompanying notes to consolidated financial statements and management's
discussion and analysis of financial condition and results of operations.






                                    Page 4

                         LabOne, Inc. and Subsidiaries
                    Consolidated Statements of Cash Flows
                                (as restated)
                                                       Three months ended
                                                            March 31,
                                                        1999         1998
                                                      ---------    ---------
Cash provided by (used for) operations:
   Net earnings                                     $ 1,853,400    1,917,192
   Adjustments to reconcile net earnings
    to net cash provided by operations:
      Depreciation and amortization                   1,406,681    1,221,894
      Provision for loss on accounts receivable         604,749      226,274
      Loss (gain) on disposal of
      Property and equipment                           (287,107)         127
      Deferred Income taxes                             831,498      (29,551)
   Changes in:
     Accounts receivable                             (1,565,413)  (3,019,852)
     Income taxes                                       104,430    1,113,197
     Inventories                                        437,719      309,781
     Prepaid expenses and other current assets           16,641       (8,219)
     Accounts payable                                  (464,305)   1,002,187
     Accrued payroll & benefits                      (1,065,562)  (1,551,064)
     Other Accrued expenses                           1,041,712      126,706
     Other current liabilities                           69,846       (8,364)
                                                     ----------    ----------
        Net cash provided by operations               2,984,289    1,300,308
                                                     ----------    ----------
Cash provided by (used for) investment transactions:
   Purchases of investments held to maturity               -      (4,467,421)
   Proceeds from maturities of investments held
     to maturity                                           -         701,894
   Property, plant and equipment, net                (3,854,833)  (1,724,596)
   Other                                                 (4,423)         537
                                                    ----------    ----------
        Net cash used for investment transactions    (3,859,256)  (5,489,586)
                                                     ----------   ----------
Cash provided by (used for) financing transactions:
   Issuance of treasury stock, net of proceeds
     from the exercise of stock options                    -          69,090
   Payments on long term debt - capital lease            (2,966)        -
   Cash dividends                                    (2,396,061)  (2,364,400)
                                                     ----------   ----------
        Net cash used for financing transactions     (2,399,027)  (2,295,310)
                                                     ----------    ----------
Effect of foreign currency translation                   14,510        9,338
                                                     ----------   ----------
        Net decrease in cash and cash equivalents    (3,259,484)  (6,475,250)
Cash and cash equivalents - beginning of period      10,177,740   18,284,672
                                                     ----------   ----------
Cash and cash equivalents - end of period          $  6,918,256   11,809,422
                                                     ==========   ==========
Supplemental disclosures of cash flow information:
   Cash paid during the period for:
      Interest                                       $  326,590         -
      Income Taxes                                   $  162,464      109,155
                                                     ==========    ==========
See accompanying notes to consolidated financial statements and management's
discussion and analysis of financial condition and results of operations.
                                 Page 5
                        LabOne, Inc. and Subsidiaries
            Notes to Consolidated Financial Statements (as restated)
                          March 31, 1999 and 1998

The accompanying consolidated financial statements include the accounts of
LabOne, Inc. and its wholly-owned subsidiaries Lab One Canada Inc. and
Systematic Business Services, Inc. (SBSI).  All significant intercompany
transactions have been eliminated in consolidation.

The financial information furnished herein as of March 31, 1999 and for the
periods ended March 31, 1999 and 1998 is unaudited; however, in the opinion of
management, it reflects all adjustments, consisting of normal recurring
adjustments, which are necessary to fairly state the Company's financial
position, the results of its operations and cash flows.  The balance sheet
information as of December 31, 1998 has been derived from the audited
financial statements as of that date.  The financial statements have been
prepared in conformity with generally accepted accounting principles
appropriate in the circumstances, and included in the financial statements
are certain amounts based on management's estimates and judgments.

The financial information herein is not necessarily representative of a full
year's operations because levels of sales, capital additions and other factors
fluctuate throughout the year.  These same considerations apply to all year-
to-year comparisons.  See the Company's Annual Report on Form 10-K for the
year ended December 31, 1998, for additional information not required by this
Quarterly Report on Form 10-Q.

As requested by the staff of the Securities and Exchange Commission in the
second quarter of 1999, the Company conducted a review of the useful life of
certain intangible assets which arose in 1997 in connection with the
acquisition described in the last paragraph of Note 3.  The Company concluded
that the life of such assets be changed from fifteen to five years and
amortization be restated retroactively.  The effect of this restatement is as
follows:
                       Period ended March 31, 1999  Period ended March 31, 1998
                         -----------------------      -----------------------
                        As Previously               AS Previously
                          Reported    As Restated      Reported    As Restated
                        -----------   -----------    -----------   -----------
Earnings before taxes   $ 3,048,272     2,910,663     3,296,583     3,158,974
Net earnings              1,947,023     1,853,400     2,000,063     1,917,192
Basic earnings per share       0.15          0.14          0.15          0.15
Diluted earnings per share     0.15          0.14          0.15          0.14

Effective October 30, 1998, LabOne acquired SBSI, a Missouri corporation.
SBSI provides telephone inspections, motor vehicle reports, attending
physician statements and claims investigation services to life and health
insurers nationwide.

LabOne is currently 80.5% owned by Lab Holdings, Inc.  On March 8, 1999,
LabOne and Lab Holdings jointly announced that the Boards of Directors of both
companies had approved an agreement to merge the two companies.  If
consummated, the proposed merger will have several effects which are fully
discussed in the Registration Statement on Form S-4 filed by Lab Holdings with
the United States Securities and Exchange Commission on April 13, 1999 (File
No. 333-76131), which may be amended from time to time.  Representatives of
Lab Holdings negotiated the merger with a Special Committee of independent
directors of LabOne that was established to represent the interests of the
holders of the 19.5% of common stock of LabOne not owned by Lab Holdings.  The
Special Committee, which had the assistance of independent legal and financial
advisors, also approved the merger agreement and recommended its approval by
the LabOne board and stockholders.  The merger is expected to close in July
                                     Page 6
following the satisfaction of a number of closing conditions.  These include
approval by the holders of two-thirds of the outstanding Lab Holdings shares
and a majority of the shares voted by LabOne stockholders other than Lab
Holdings and its affiliates.  Financing must also be obtained sufficient to
satisfy cash elections after the use of available cash of LabOne and Lab
Holdings

     Forward Looking Statements
This Quarterly report on Form 10-Q may contain "forward-looking statements,"
including projections, statements of plans and objectives, statements of
future economic performance and statements of assumptions underlying such
statements.  Forward-looking statements involve known and unknown risks and
uncertainties.  Many factors could cause actual results to differ materially
from those that may be expressed or implied in such forward-looking
statements, including, but not limited to, the volume and pricing of
laboratory tests performed by the Company, competition, the extent of market
acceptance of the Company's testing services in the healthcare and substance
abuse testing industries, general economic conditions and other factors
detailed from time to time in the Company's reports and registration
statements filed with the Securities and Exchange Commission, including the
Cautionary Statement filed as exhibit 99 to the Company's Annual Report on
Form 10-K for the year ended December 31, 1998.

     Business Segment Information
The company operates in three lines of business:  insurance risk appraisal
testing, clinical diagnostic testing and substance abuse testing.  The
following table presents selected financial information for each segment:
       (as restated)                    Three Months Ended March 31,
                                             1999         1998
                                             ----         ----
Sales:
   Insurance                            $ 17,584,247    16,822,452
   Clinical                                5,957,526     3,654,043
   Substance abuse testing                 3,786,312     2,856,939
                                          ----------    ----------
Total sales                             $ 27,328,085    23,333,434
                                          ==========    ==========
Operating income (loss):
   Insurance                            $  4,014,225     5,074,655
   Clinical                                 (958,778)   (1,935,046)
   Substance abuse testing                  (118,940)     (178,786)
   General corporate income (expense)        176,154       (34,748)
                                           ---------     ---------
Total earnings from operations             3,112,661     2,926,075
   Other income (expense)                   (201,998)      232,899
                                           ---------     ---------
Earnings before income taxes            $  2,910,663     3,158,974
                                           =========     =========
Company assets classified as corporate increased significantly due to bond
proceeds and construction of the new facility. There were no material changes
in assets in the other segments, or in the basis of segmentation or
measurement of segment operating income or loss.

         Contingencies     Tax Assessment
The Comptroller of the State of Texas has conducted an audit of LabOne for
sales tax compliance and contends that LabOne's insurance laboratory testing
services are taxable under the Texas tax code and has issued an audit
assessment, including interest and penalties, of approximately $1.9 million.
The Company has appealed this assessment arguing that its services do not fit
                                    Page 7
within the definition of insurance services under the Texas code.  The
assessment is under review by the Texas State Hearing Attorney.  At this time,
the Company is unable to estimate the possible liability, if any, that may be
incurred as a result of this assessment.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
         CONDITION AND RESULTS OF OPERATIONS.
RESULTS OF OPERATIONS
---------------------
                        Selected Financial Data (as restated)
<TABLE>
<S>                              <C>            <C>          <C>
                                      Three Months Ended       % Increase
                                          March 31,             (Decrease)
                                      1999          1998
                                   -----------   -----------   ----------
   Sales                          $ 27,328,085    23,333,434         17%
   Net earnings                      1,853,400     1,917,192         (3%)
   Diluted earnings per common share   $0.14          0.14
   Cash dividends per common share     $0.18          0.18
</TABLE>
The Company provides high-quality laboratory testing services to insurance
companies, physicians and employers.

LabOne provides risk-appraisal laboratory services to the insurance industry.
The tests performed by the Company are specifically designed to assist an
insurance company in objectively evaluating the mortality and morbidity risks
posed by policy applicants.  The majority of the testing is performed on
specimens of individual life insurance policy applicants.  The Company also
provides testing services on specimens of individuals applying for individual
and group medical and disability policies.  Through its subsidiary, SBSI, the
Company provides telephone inspections,  motor vehicle reports, attending
physician statements, and claims investigation services to life and health
insurers nationwide.

LabOne's clinical testing services are provided to the healthcare industry to
aid in the diagnosis and treatment of patients.  LabOne operates only one
highly automated and centralized laboratory, which the Company believes has
significant economic advantages over other conventional laboratory
competitors.  LabOne markets its clinical testing services to the payers of
healthcare--insurance companies and self-insured groups.  The Company does
this through Lab Card(, a Laboratory Benefits Management (LBM) program.

The Lab Card Program provides laboratory testing at reduced rates as compared
to traditional laboratories.  It uses a unique benefit design that shares the
cost savings with the patient, creating an incentive for the patient to help
direct laboratory work to LabOne.  Under the Program, the patient incurs no
out-of-pocket expense when the Lab Card is used, and the insurance company or
self-insured group receives substantial savings on its laboratory charges.
The Company's LBM programs, including BlueCross BlueShield of Tennessee and
the Lab Card program, have more than 2.3 million lives enrolled.

LabOne is certified by the Substance Abuse and Mental Health Services
Administration to perform substance abuse testing services for
federally regulated employers and is currently marketing these services
throughout the country to both regulated and nonregulated employers.  The
Company's rapid turnaround times and multiple testing options help clients
reduce downtime for affected employees and meet mandated drug screening
guidelines.
                                     Page 8
On July 1, 1999, the Company announced a restatement of earnings for the years
ended December 31, 1997 and 1998, and for the quarters ended March 31, 1999
and 1998.  As requested by the staff of the Securities and Exchange
Commission, the Company has changed the amortization schedule from fifteen
years to five years on a customer list acquired during the first quarter 1997.
The Company's original amortization period was based on historical
performance, however the SEC has requested the amortization period be reduced
to five years.  The amortization expense was originally reported at $69,000
in the first quarter 1999 and 1998, and has been restated to $206,000 in both
periods.  This restatement is not the result of any changes in
customer relationships and has no effect on any present or future cash flows.

FIRST QUARTER ANALYSIS

Net sales increased 17% in the first quarter 1999 to $27.3 million from $23.3
million in the first quarter 1998.  The increase of $4.0 million is due to
increases in clinical laboratory revenue of $2.3 million, substance abuse
testing (SAT) revenue of $0.9 million and insurance services revenue of $0.8
million.

Clinical diagnostic testing revenue increased from $3.7 million to $6.0
million for the quarter due to increased testing volumes partially offset by a
6% decrease in average revenue per patient.  SAT revenue increased from $2.9
million in 1998 to $3.8 million in 1999 due to a 35% increase in testing
volumes as compared to last year.

The insurance services division revenue increased $0.8 million due to the
addition of SBSI revenue and growth in non laboratory services revenue,
partially offset by lower laboratory and kit revenue.  SBSI was acquired in
October 1998 and contributed $1.9 million, and non laboratory services revenue
increased $0.3 million over last year.  Insurance laboratory testing revenue
decreased $0.8 million as a result of reductions in volume and price.  The
total number of insurance applicants tested in the first quarter 1999
decreased by 4% as compared to the same quarter last year due to competitive
pressures.  Average revenue per applicant decreased 2.5% primarily due to
price reductions and a shift in product mix to lower priced products.  Kit and
container revenue declined due to a decrease in the number of kits sold.

Cost of sales increased $2.7 million or 21% in the first quarter 1999 as
compared to the prior year, due to increases in payroll, outside services such
as paramed collections and state motor vehicle report fees, and postage
expense.  A significant portion of these increases are related to the addition
of SBSI.  Laboratory overtime and regular labor expense increased related to
the move to the new facility.  These increases were partially offset by a
decrease in insurance kit expenses due to lower sales volumes.  Clinical cost
of sales expenses were $3.9 million as compared to $3.4 million in the first
quarter 1998.  SAT cost of sales expenses were $2.8 million as compared to
$2.1 million in the first quarter 1998.  Insurance cost of sales expenses
increased from $7.5 million to $9.0 million primarily due to the addition of
SBSI.

As a result of the above factors, gross profit for the quarter increased $1.3
million or 13% from $10.4 million in 1998 to $11.7 million in 1999.  Clinical
gross profit increased $1.7 million on an increase in revenue of $2.3 million.
SAT gross profit increased $0.2 million on an increase in revenue of $0.9
million.  Insurance gross profit decreased $0.7 million or 7%.


                                     Page 9

Selling, general and administrative expenses increased $1.1 million or 15% in
the first quarter 1999 as compared to the prior year due primarily to the
inclusion of SBSI and increases in bad debt, depreciation and moving expenses.
Bad debt expense increased primarily due to the revenue growth in clinical and
SAT segments which have inherently higher bad debt experience than the
insurance testing segment.  Insurance expenditures increased to $4.6 million
for the quarter as compared to $4.2 million in 1998 primarily due to the
addition of SBSI.  Total clinical expenditures increased $0.8 million to $3.0
million in 1999 primarily due to an increase in corporate overhead allocations
to $0.9 million in 1999 from $0.6 million in 1998 and an increase in bad debt
expense.  SAT expenditures were $1.1 million as compared to $1.0 million last
year. On March 25, 1999, LabOne closed on the sale of its former laboratory
facility, resulting in a net gain of $0.3 million.  The gain resulted from the
sales price of $2.0 million being greater than originally anticipated.  The
$2.5 million sale of the former administration building is scheduled to be
closed on June 1, 1999.  Depreciation expense on the new facility is expected
to be less than $0.3 million per quarter.

Earnings from operations increased from $2.9 million in the first quarter 1998
to $3.1 million in 1999.  The clinical segment improved $1.0 million to an
operating loss of $1.0 million.  The SAT segment improved $0.1 million from an
operating loss of $0.2 million in the first quarter 1998 to a loss of $0.1
million in 1999.  The insurance segment declined $1.1 million to an operating
profit of $4.0 million.

Non operating expense increased $0.4 million primarily due to interest expense
on the industrial revenue bonds and a reduction in capital available for
investment.  The effective income tax rate declined from 39% in 1998 to 36% in
1999 due to state income tax incentives.

The combined effect of the above factors resulted in net earnings of $1.9
million or $0.14 per share in the first quarter 1999 as compared to $1.9
million or $0.14 per share in the same period last year.

FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES
---------------------------------------------------

LabOne's working capital position decreased by $4.8 million to $21.1 million
at March 31, 1999 from $25.9 million at December 31, 1998.  This decrease is
primarily due to dividends paid and capital additions exceeding cash provided
by operations.  Cash flow from operations increased by $1.7 million in the
first quarter 1999 as compared to 1998.  The increase is primarily
attributable to slower growth in accounts receivable.

Additions to property, plant and equipment, net of the sale of the former
laboratory facility, were $3.9 million in the first quarter 1999, primarily
related to construction and fixtures for the new facility.  Net additions in
the first quarter 1998 were $1.7 million.  Capital additions are expected to
be approximately $5.0 million annually.

In February 1999, LabOne's Board of Directors declared a dividend of $0.18 per
common share.  This dividend was paid on March 2, 1999, to stockholders of
record as of February 23, 1999, and totaled approximately $2.4 million.  The
board reviews the dividend payment policy on a periodic basis.  There are
currently no restrictions that would limit the Company's ability to make
future dividend payments.


                                        Page 10

If the proposed merger between LabOne and Lab Holdings is consummated, the
future dividend policy of the combined company in the merger will be
determined by its new Board of Directors, a majority of whom will be
independent non-management directors.  Although nine of the eleven current
LabOne directors are expected to continue as directors of the combined
company, there can be no assurance as to any dividend determinations by that
board in the future.  That determination will be subject to the financial
condition, operating results, and liquidity of the combined company and
numerous other factors.  In addition, the pursuit by the combined company of
LabOne's growth and diversification strategy, the increased financial leverage
that is expected to result from the merger, changes in the market for LabOne's
products and services, negative impacts caused by other risks described in the
Registration Statement on Form S-4 filed by Lab Holdings with the United
States Securities and Exchange Commission on April 13, 1999 (File No. 333-
76131), which may be amended from time to time, or any of them singly or
together with other factors could influence the board of the combined company
to reduce or eliminate the quarterly dividend.

Under the merger agreement, LabOne shareholders (other than Lab Holdings) may
elect to exchange each LabOne share for either one share of the combined
company, $12.75 in cash, or a combination of shares and cash.  Cash elections
are subject to an aggregate cash limit of $16.6 million.  It is expected that
the combined company will need to borrow up to $13.6 million to satisfy cash
elections in excess of $3 million.  Additional cash could be needed if any Lab
Holdings shareholders perfect dissenters' rights.  These additional borrowings
will increase annual interest expense and subject the combined company to the
normal risks associated with debt financing.  However, the amount of these
borrowings is not expected to have a negative impact on earnings per share
because the increased borrowing expense would be offset by the reduction in
the number of shares of the combined company issued in the merger as a result
of cash elections by LabOne stockholders.  The additional financial leverage
could also impair the ability of the combined company to pursue acquisition
and growth strategies that would otherwise be available or impact future
operating results due to higher debt service in the event that future
acquisitions are completed.  Existing loan agreements do not contain covenants
that will directly prohibit the board of directors of the combined company
from continuing Holdings' quarterly dividends at the current amount.  However,
the increased debt combined with other circumstances could cause the board of
the combined company to reduce or discontinue the quarterly dividend.  Other
circumstances include negative operating results, acquisition or other
expenditures or commitments incurred to continue LabOne's diversification and
growth strategy, or the effect of general financial covenants contained in the
loan agreements.

One effect of the merger will be to add transaction goodwill to the balance
sheet of the combined company in an estimated amount ranging from about $22.2
million to $24.9 million.  This transaction goodwill reflects the expected
difference between the cost of LabOne shares that Lab Holdings will be treated
as acquiring in the merger and the fair value of the LabOne net assets
allocated to these acquired shares.  If the merger is consummated, the
combined company's balance sheet will also include about $6.0 million in
existing historical goodwill that currently is a Lab Holdings asset that
resulted from Holding's prior acquisitions of LabOne stock.  Following the
merger, this historical and transaction goodwill is expected to negatively
impact reported earnings of the combined company at an estimated annual rate
from about $2.6 million to $2.8 million until the historical goodwill is fully
amortized in April 2003, and thereafter at an estimated annual rate from about
$1.1 million to $1.3 million until the 20th anniversary of the merger.  The

                                        Page 11
amounts in this paragraph are hypothetical assuming that the merger had
occurred as shown on the pro forma financial statements included in the above
Registration Statement.  The actual amount of goodwill incurred in the merger
will depend on the number of combined company shares issued in the merger, the
actual amount of transaction costs and the fair value of the LabOne net assets
at the time of the merger.

The total number of shares of LabOne stock held in treasury at March 31, 1999
was approximately 1.7 million at a total cost of $20.2 million or $11.97 per
share.  The Company had no short-term borrowings in the first quarter 1999.
The Company expects to fund operations and future dividend payments from a
combination of cash flows from operations, cash reserves and short term
borrowings.  Proceeds from the industrial revenue bond have been used to
finance the construction of the Company's new facility project.  Interest on
the bond is based on a taxable seven day variable rate and is currently
approximately 5.7%.  The Company expects to repay the bond over 11 years at
$1.85 million per year plus interest.  At March 31, 1999, LabOne had total
cash and investments of $6.9 million as compared to $10.2 million at December
31, 1998.

YEAR 2000
---------
LabOne is actively addressing Year 2000 computer concerns.  The company has
established an oversight committee which includes management from all parts of
the Company and meets periodically to review progress.  The Company's
laboratory operating systems and its business processing systems were
completely rewritten in the past ten years and were brought into compliance
with Year 2000 date standards at that time.  As part of construction of the
new facility, certified compliant security systems, time clocks and heating
and cooling systems (non-IT systems) were installed.  The Company expects to
complete all remaining internal Year 2000 objectives by the end of the second
quarter, 1999.

LabOne is assessing the Year 2000 preparation and contingency plans of the
Company's clients and vendors.  LabOne has material relationships and
dependencies with its primary telecommunications provider, Sprint Corp., its
inbound shipping provider, Airborne Express, and municipal services providers.
In the event of a service interruption, the Company has the ability to switch
telecommunications services to AT&T at any time, and maintains backup
electrical generators capable of meeting its electrical needs.  LabOne
currently tracks and controls routing of its inbound specimens and can use
USPS, airlines and other common carriers or express delivery services in the
event of delivery problems with Airborne Express.  The Company currently
maintains approximately 8 weeks supply of most laboratory supplies, and does
not expect significant problems in obtaining supplies.  The Company continues
to review the Year 2000 plans of these providers, and does not currently
expect significant problems in these areas, however, there can be no assurance
that the systems of clients and vendors will be converted to address Year 2000
problems in a timely and effective manner or that such conversions will be
compatible with the Company's computer systems.

Resources dedicated to the remaining effort are expected to cost less than
$0.2 million and are not considered a material expense to the Company.  These
efforts have not caused delay to the Company's other ongoing information
systems projects.  LabOne has not hired any outside consultants or other
independent validation provider at this time, and does not expect to do so.

There can be no assurance that the Company's adjustments to its computer
systems will completely eliminate all Year 2000 problems.  Failure to properly
                                     Page 12
address the Year 2000 problem could have a material adverse effect on the
Company's business, financial condition and results of operations.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

A foreign currency risk exposure exists due to billing Canadian subsidiary
revenue in Canadian dollars and the direct laboratory expenses associated with
this revenue being incurred in US dollars.  This exposure is not considered to
be material.  Any future material Canadian currency fluctuations against the
US$ could result in a decision to hedge future foreign currency cash flows, or
to increase Canadian prices.

An interest rate risk exposure exists due to LabOne's liability of $20 million
in industrial revenue bonds.  The interest expense incurred on these bonds is
based on a taxable seven day variable rate, which including letter of credit
and remarketing fees, is approximately 5.7% as of May 1, 1999.  This exposure
is not considered material.  Any future increase in interest rates would
result in additional interest expense and could result in a decision to enter
into a long-term interest rate swap transaction.

PART II.  OTHER INFORMATION

Item 6. -  Exhibits and Reports on Form 8-K
   (a)   Exhibits

2.   Form of Agreement and Plan of Merger, by and between Lab Holdings, Inc.
     and LabOne, Inc., as amended and restated, dated March 7, 1999
     (incorporated by reference to Exhibit 2.3 to Lab Holdings' Registration
     Statement on Form S-4 filed April 13, 1999, file No. 333-76131).

27.  Financial Data Schedule - as filed electronically by the
     Registrant in conjunction with this first quarter 1999 Form 10-Q.

   (b)   Reports on Form 8-K

     A Form 8-K current report dated March 8, 1999, was filed with the
Commission reporting under Other Events that LabOne and Lab Holdings, Inc. had
entered into an agreement to merge the two companies.

                              SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

     LabOne, Inc.

     Date:  July 2, 1999                   By  /s/ Kurt E. Gruenbacher
                                                ------------------------
                                                 Kurt E. Gruenbacher,
                                                 V.P. Finance, CAO
                                                 and Treasurer

     Date:  July 2, 1999                   By  /s/ Robert D. Thompson
                                                ------------------------
                                                 Robert D. Thompson,
                                                 Executive V.P., Chief
                                                 Operating Officer and
                                                 Chief Financial Officer
                                      Page 13